微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议

智通财经02-03

智通财经APP讯，微芯生物(688321.SH)发布公告，公司与Nizhny Novgorod Chemical Pharmaceutical Plant(简称“Nizhpharm”)就公司产品西达本胺签署许可及分销协议。根据协议，Nizhpharm将获得西达本胺在亚美尼亚、阿塞拜疆、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦、摩尔多瓦、蒙古、俄罗斯、塔吉克斯坦、乌兹别克斯坦、格鲁吉亚和土库曼斯坦自生效日...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608005829?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-03 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608005829","market":"sh","top_or_hot":-1,"title":"微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，微芯生物(688321.SH)发布公告，公司与Nizhny Novgorod Chemical Pharmaceutical Plant(简称“Nizhpharm”)就公司产品西达本胺签署许可及分销协议。根据协议，Nizhpharm将获得西达本胺在亚美尼亚、阿塞拜疆、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦、摩尔多瓦、蒙古、俄罗斯、塔吉克斯坦、乌兹别克斯坦、格鲁吉亚和土库曼斯坦自生效日...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401070.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微芯生物(688321.SH)与Nizhpharm签署西达本胺许可及分销协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 17:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401070.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微芯生物(688321.SH)发布公告，公司与Nizhny Novgorod Chemical Pharmaceutical Plant(简称“Nizhpharm”)就公司产品西达本胺签署许可及分销协议。根据协议，Nizhpharm将获得西达本胺在亚美尼亚、阿塞拜疆、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦、摩尔多瓦、蒙古、俄罗斯、塔吉克斯坦、乌兹别克斯坦、格鲁吉亚和土库曼斯坦自生效日...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401070.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688321","symbol_name":"微芯生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401070.html","article_id":"2608005829","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608005829","pubTimestamp":1770111245,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微芯生物 发布公告，公司与Nizhny Novgorod Chemical Pharmaceutical Plant就公司产品西达本胺签署许可及分销协议。Nizhpharm 将自行负责产品在授权地区的研发、上市注册、二次包装、运输及商业化销售工作。Nizhpharm 将按照协议的约定价格从公司采购产品用于授权区域内的商业化销售。Nizhpharm 集团是俄罗斯联邦领先的制药企业之一，拥有逾百年历史。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688321":"微芯生物","BK0239":"医药制造"},"translate_title":"Microchip Biotech (688321. SH) and Nizhpharm signed a license and distribution agreement for chidamide","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688321":1.5},"content_text":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司与Nizhny Novgorod Chemical Pharmaceutical Plant(简称“Nizhpharm”)就公司产品西达本胺签署许可及分销协议。根据协议，Nizhpharm将获得西达本胺在亚美尼亚、阿塞拜疆、白俄罗斯、哈萨克斯坦、吉尔吉斯斯坦、摩尔多瓦、蒙古、俄罗斯、塔吉克斯坦、乌兹别克斯坦、格鲁吉亚和土库曼斯坦自生效日起实际由其政府管辖的领土范围，以及未来任何首都位于上述任一领土范围内的国家(如适用)地区(简称“授权地区”)的研发、注册和商业化的独家权利。Nizhpharm 将自行负责产品在授权地区的研发、上市注册、二次包装、运输及商业化销售工作。Nizhpharm 将按照协议的约定价格从公司采购产品用于授权区域内的商业化销售。Nizhpharm 集团是俄罗斯联邦领先的制药企业之一，拥有逾百年历史。Nizhpharm 专注于针对患者及医生需求高度未获满足的关键治疗领域，从事处方药与非处方药的研发、生产及商业化运营，旗下设有符合GMP 标准的现代化生产基地，并拥有覆盖全国的完善商业网络体系。西达本胺(Chidamide;商品名为“爱谱沙/Epidaza”)是全球首个亚型选择性组蛋白去乙酰化酶(HDAC)抑制剂，开创了中国创新药对欧美专利授权(License-out)的先河。公司将西达本胺在授权区域内的相关知识产权以及在当地产品的研发及商业化销售权独家授予 Nizhpharm。Nizhpharm 将单独负责产品在授权区域内的研发、上市注册、二次包装、运输以及商业化销售工作。协议生效后，公司将收到总计1000万元人民币的首付款、近期监管材料转移里程碑及总计1000万元人民币的当地注册上市里程碑。作为在授权区域的商业化合作伙伴，Nizhpharm 将按照协议的约定价格从公司采购产品用于授权区域内的销售;公司将以产品在授权区域内实现的净销售额为计算基础，从Nizhpharm 取得高双位数比例的销售分成。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608005829","isCrawlerRequest":true}